Background and activities
Scientific, academic and artistic work
A selection of recent journal publications, artistic productions, books, including book and report excerpts. See all publications in the database
- (2015) Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups. Acta Haematologica. vol. 133 (4).
- (2015) Content of endothelial progenitor cells in autologous stem cellgrafts predict survival after transplantation for multiplemyeloma. Biology of blood and marrow transplantation. vol. 21 (5).
- (2015) Rituximab as Second-Line Treatment for Adult Immune Thrombocytopenia (the Ritp Trial): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet. vol. 385 (9978).
- (2015) Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplantation. vol. 50 (6).
- (2015) MYC amplifications in myeloma cell lines; correlation with MYC-inhibitor efficacy. OncoTarget.
- (2015) Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Communication and Signaling. vol. 13 (1).
- (2015) BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood Cancer Journal.
- (2015) Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nature Communications. vol. 6.
- (2014) MYC gene copy number determine MYC expression and sensitivity to a MYC-inhibitor in multiple myeloma cells. Cancer Research. vol. 74.
- (2014) Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. American Journal of Hematology. vol. 89 (4).
- (2014) Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood Cancer Journal. vol. 4.
- (2014) Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. The Lancet Oncology. vol. 15 (3).
- (2014) Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients. Biomarker Research. vol. 2 (1).
- (2014) The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: Recommendations from the European Myeloma Network. Haematologica. vol. 99 (6).
- (2013) Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate. European Journal of Haematology. vol. 91 (4).
- (2013) Dependency on c-MYC in multiple myeloma. Cancer Research. vol. 73 (8).
- (2013) Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. vol. 121 (23).
- (2013) A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells. Journal of Biomolecular Screening. vol. 18 (6).
- (2013) Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. vol. 98 (1).
- (2013) HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Experimental Hematology. vol. 41 (7).